DF/HCC Renal Cancer SPORE

DF/HCC 肾癌孢子

• 批准号: 6801547
• 负责人: Michael Benjamin Atkins
• 金额: $ 244.77万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-18 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6801547
• 关键词: clinical research; renal cell carcinoma

DESCRIPTION (provided by applicant): This application represents the creation of a Specialized Program of Research Excellence in Renal Cancer originating from the Renal Cancer Program-in-Development of the newly configured Dana-Farber Harvard Cancer Center (DF/HCC) and the Beth Israel Deaconess Medical Center. The DF/HCC Renal Cancer SPORE includes investigators from all the Harvard affiliated hospitals - the Beth Israel Deaconess Medical Center, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Brigham and Women's Hospital, and the Children's Hospital Medical Center, as well as the Harvard School of Public Health. Five major projects are supported through this application including: 1) Identification of markers for early detection and monitoring of high-risk RCC populations; 2) Inhibition of VHL-regulated growth factor pathways for treatment of RCC; 3) Combination radiofrequency ablation and antivascular/anitangiogenesis therapy for RCC; 4) Identification of molecular and immunologic correlates of RCC prognosis and responsiveness to therapy, and 5) Dendritic cell/tumor fusions in conjunction with IL-12 as novel immunotherapy for RCC. These projects are integrated by four cores. These are: 1) Administration, Evaluation and Planning; 2) Biostatistics; 3) Tissue Acquisition, Pathology and Clinical Data, and 4) Monitoring. This SPORE application outlines a Developmental Projects Program which includes a plan for selection and review of projects, and eight sample projects that could be considered for support. We also include a Career Development Award Program which outlines a mechanism for the identification, support, and review of talented young investigators in renal cancer. The overall goal of the DF/HCC Renal Cancer SPORE is the translation of biological and technological advances into clinically meaningful advances for patients with renal cancer.

描述（由申请人提供）：此申请代表了创建一个专业的肾癌研究卓越研究计划，该计划源自新配置的Dana-Farber Harvard Cancer Center（DF/HCC）和Beth Israel Deaconess Medical Center的新配置的Dana-Farber Harvard Cancer Center（DF/HCC）。 DF/HCC肾癌孢子包括来自哈佛大学的所有医院的研究人员 - 贝丝以色列女执事医疗中心，达纳 - 弗尔伯癌研究所，马萨诸塞州综合医院，布里格姆和妇女医院以及儿童医院医院以及哈佛公共卫生学院。 通过此应用程序支持了五个主要项目，包括：1）标记以早期检测和监测高风险RCC人群的标记； 2）抑制VHL调节的生长因子途径用于治疗RCC； 3）RCC的射频消融和抗血管/抗血管生成疗法； 4）鉴定RCC预后和对治疗的反应性的分子和免疫学相关性，以及5）与IL-12结合使用的树突状细胞/肿瘤融合作为RCC的新型免疫疗法。 这些项目由四个核心整合。这些是：1）行政，评估和计划； 2）生物统计学； 3）组织采集，病理和临床数据以及4）监测。 该孢子应用程序概述了一个开发项目计划，其中包括选择和审查项目的计划，以及八个可以考虑支持的示例项目。 我们还包括一项职业发展奖计划，概述了肾脏癌的才华横溢的年轻调查人员的识别，支持和审查的机制。 DF/HCC肾脏癌孢子的总体目标是将生物学和技术进步转化为肾脏癌患者临床意义的进展。